Vaxart, Inc. - Common Stock
0.3500+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCQX · VXRT · USD
Key Stats
Market Cap
80.12MP/E (TTM)
-Basic EPS (TTM)
-0.23Dividend Yield
0%Recent Filings
8-K
BARDA narrows Vaxart COVID funding
Vaxart received a follow-up notice on October 8, 2025, from ATI confirming BARDA's decision to exclude paused work under its COVID-19 vaccine project agreement, while allowing follow-up for the approximately 5,000 enrolled trial participants and related funding. This delimitation halts broader efforts but preserves data collection from the Phase 2b study. The company views this evidence as a potential foundation to advance its oral pill COVID program. Yet risks loom if trial outcomes disappoint.
8-K
Vaxart withdraws stockholder proposal
Vaxart withdrew its key stockholder proposal on September 18, 2025, scrapping the reconvened special meeting set for September 19. This abrupt pivot follows the initial adjournment on September 5 to gather more votes. The move leaves the company's strategic plans in limbo, with no further details disclosed.
8-K
Vaxart adjourns stockholder vote
Vaxart adjourned its special stockholder meeting from September 5 to September 19, 2025, to give investors more time to vote on the reverse stock split proposal amid recent board changes and potential governance updates. With 64.25% quorum achieved, the board aims to boost Nasdaq compliance and advance vaccine science. Stockholders can still vote by September 18. Delays risk ongoing listing uncertainty.
8-K
Vaxart Chairman Retires
Vaxart's board chairman, Michael J. Finney, Ph.D., announced his retirement effective September 30, 2025, for personal reasons, with no disagreements over company matters. The board shrinks from six to five members, and will soon discuss leadership and composition to sustain scientific progress. His tenure shaped Vaxart's oral vaccine platform. No successor named yet.
8-K
Nasdaq grants Vaxart compliance extension
Vaxart dodged delisting on August 27, 2025, when Nasdaq's Panel granted a conditional extension to stay listed. The biotech must secure shareholder approval for a reverse stock split by September 5, execute it by October 6, and hit the $1 minimum bid price by October 17—or face removal. This buys time in a tough vaccine market, but hinges on stockholder votes. Failure triggers delisting.
BVAXD
BioVaxys Technology Corp.
0.15-0.03
GOVX
GeoVax Labs, Inc.
0.55-0.05
HLVX
HilleVax, Inc.
2.09+0.00
INO
Inovio Pharmaceuticals, Inc.
2.43-0.15
MRNA
Moderna, Inc.
24.70-0.65
NNVC
NanoViricides, Inc.
1.86+0.33
NVAX
Novavax, Inc.
8.38-0.14
PCVX
Vaxcyte, Inc.
43.52-1.05
VIR
Vir Biotechnology, Inc.
5.91-0.52
VIRX
Viracta Therapeutics, Inc.
0.01+0.00